Financial Performance Overview
HealthCare Global Enterprises Limited (HCG) reported strong financial results for FY26 with standalone revenue from operations reaching ₹25,384.29 million, representing 14.44% growth compared to FY25. Profit before exceptional items and tax increased by 25.50% to ₹714.91 million. The company reported foreign exchange earnings of ₹17.52 crore with expenditure of ₹7.08 crore for the fiscal year.
Capital Raising and Corporate Actions
HCG successfully completed a rights issue raising ₹424.68 crores by issuing 8,294,566 equity shares at ₹512 per share. Proceeds were utilized for debt repayment (₹170 crores), partial payment for additional stake in Vizag Hospital (₹154.04 crores), and general corporate purposes. The company also modified its ESOP 2021 Scheme to cash settlement, paying ₹580.80 million for 1,619,741 vested options.
Significant Ownership Changes and Board Restructuring
In a major corporate development, Hector Asia Holdings II Pte Ltd (affiliate of KKR & Co. Inc.) acquired 51.59% stake from Aceso Company Pte. Ltd. at ₹445 per share on May 30, 2025, resulting in a change in control. This triggered significant board composition changes with Dr. B.S. Ajaikumar appointed as Non-Executive Chairman, Mrs. Anjali Ajaikumar Rossi as Non-Executive Director, and KKR nominees Mr. Akshay Tanna and Ms. Simrun Mehta joining the board. Dr. Manish Mattoo was appointed as Executive Director and CEO effective June 30, 2025.
Strategic Investments and Divestments
HCG acquired an additional 34% equity stake in Vizag Hospital and Cancer Research Centre Private Limited on April 13, 2026 for ₹1,545.02 million, increasing its total holding. Concurrently, the company initiated divestment of its Milann fertility business (BACC Health Care Private Limited) to Inviga Healthcare Fund I for ₹376.44 million, recognizing an impairment loss of ₹319.11 million on goodwill in FY26 financial statements.
Upcoming Annual General Meeting
The company will hold its 28th Annual General Meeting virtually on September 18, 2026. Key agenda items include adoption of FY26 financial statements, re-appointment of directors Ms. Simrun Mehta and Mr. Akshay Tanna, and approval for extending Mrs. Anjali Ajaikumar Rossi's consultancy agreement for six months at an annualized fee of ₹1.5 crore. Shareholders are also requested to ratify payment of ₹2.5 lakh plus taxes to cost auditors for FY26-27 audit services.
Operational and Regulatory Compliance
HCG maintained 22 comprehensive cancer centers (21 in India, 1 in Kenya) and 3 multi-specialty hospitals with total operational beds of 2,734. The company launched HCG Cancer Hospital in Hebbal, North Bangalore with 132-bed capacity in May 2026. Secretarial audit confirmed compliance with all applicable statutory provisions including Companies Act, 2013 and SEBI Listing Regulations. The company retained its A+ credit rating with stable outlook from ICRA.
Financial Position and Outlook
Total assets stood at ₹29.17 billion with equity of ₹16.05 billion. The rights issue proceeds significantly improved liquidity with cash and cash equivalents increasing to ₹4.74 billion. Net debt-to-equity ratio improved to 21% following the capital infusion. The company continues to focus on oncology care expansion while optimizing its portfolio through strategic divestments of non-core assets.